CRELD2 and myocardial infarction: Notably, infusing recombinant CRELD2 for 7 days after reperfusion also attenuated scarring and adverse remodeling in wild-type mice, indicating that CRELD2 protein therapy can enhance endogenous CRELD2 effects after MI and supporting the idea that infarct healing affords a time window of therapeutic opportunity wherein transient interventions can have a lasting impact on cardiac function5–7,35.